Halozyme Therapeutics EPS - Earnings per Share 2010-2024 | HALO

Halozyme Therapeutics earnings per share (EPS) for the twelve months ending June 30, 2024 was $2.57, a 51.18% increase year-over-year.

  • Halozyme Therapeutics EPS for the quarter ending June 30, 2024 was $0.72, a 28.57% increase year-over-year.
  • Halozyme Therapeutics 2023 annual EPS was $2.1, a 45.83% increase from 2022.
  • Halozyme Therapeutics 2022 annual EPS was $1.44, a 47.45% decline from 2021.
  • Halozyme Therapeutics 2021 annual EPS was $2.74, a 201.1% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Halozyme Therapeutics EPS - Earnings per Share 2010-2024 | HALO

  • Halozyme Therapeutics EPS for the quarter ending June 30, 2024 was $0.72, a 28.57% increase year-over-year.
  • Halozyme Therapeutics 2023 annual EPS was $2.1, a 45.83% increase from 2022.
  • Halozyme Therapeutics 2022 annual EPS was $1.44, a 47.45% decline from 2021.
  • Halozyme Therapeutics 2021 annual EPS was $2.74, a 201.1% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.